According to Regeneron Pharmaceuticals's latest financial reports the company has a price-to-book ratio of 3.78.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 3.68 | 6.27% |
2022-12-31 | 3.47 | -4.19% |
2021-12-31 | 3.62 | -22.61% |
2020-12-31 | 4.68 | 25.23% |
2019-12-31 | 3.73 | -19.69% |
2018-12-31 | 4.65 | -29.28% |
2017-12-31 | 6.57 | -24.45% |
2016-12-31 | 8.70 | -44.02% |
2015-12-31 | 15.5 | -5.67% |
2014-12-31 | 16.5 | 17.23% |
2013-12-31 | 14.1 | 5.17% |
2012-12-31 | 13.4 | 26.5% |
2011-12-31 | 10.6 | 89.94% |
2010-12-31 | 5.56 | 12.52% |
2009-12-31 | 4.94 | 42.48% |
2008-12-31 | 3.47 | -16.15% |
2007-12-31 | 4.14 | -31.72% |
2006-12-31 | 6.06 | -23.02% |
2005-12-31 | 7.87 | 179.3% |
2004-12-31 | 2.82 | -52.54% |
2003-12-31 | 5.94 | 5.23% |
2002-12-31 | 5.64 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.11 | 35.17% | ๐บ๐ธ USA |
Novartis NVS | 4.05 | 7.13% | ๐จ๐ญ Switzerland |
Amgen AMGN | 22.6 | 498.07% | ๐บ๐ธ USA |
Sanofi SNY | 1.38 | -63.51% | ๐ซ๐ท France |
Biogen BIIB | 1.87 | -50.47% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -83.2 | -2,302.01% | ๐บ๐ธ USA |